Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Incyte Corp (INCY) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Incyte Corp. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 879169.
Total stock buying since 2015: $245,291,742.
Total stock sales since 2015: $343,905,944.
Total stock option exercises since 2015: $99,295,098.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 125,045 | $8,710,610 | 30,690 | $1,886,632 |
| 2024 | 0 | $0 | 85,339 | $5,534,735 | 33,680 | $1,729,537 |
| 2023 | 0 | $0 | 129,881 | $10,212,029 | 111,519 | $6,144,388 |
| 2022 | 914,884 | $63,635,126 | 108,542 | $8,609,927 | 125,133 | $6,962,110 |
| 2021 | 1,608,444 | $116,033,677 | 82,611 | $6,134,766 | 52,919 | $3,839,651 |
| 2020 | 2 | $205 | 449,346 | $45,550,853 | 490,112 | $28,338,145 |
| 2019 | 0 | $0 | 390,553 | $32,490,379 | 374,907 | $8,303,058 |
| 2018 | 16,000 | $982,865 | 147,276 | $10,140,011 | 181,760 | $3,519,290 |
| 2017 | 103,500 | $13,664,670 | 410,848 | $52,860,791 | 342,250 | $12,759,047 |
| 2016 | 800,000 | $50,975,199 | 166,096 | $15,229,615 | 241,267 | $3,426,425 |
| 2015 | 0 | $0 | 1,511,521 | $148,432,228 | 6,091,040 | $22,386,815 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2018-02-21 | Gryska David W (Executive Vice President, CFO) | Sale | 1,952 | 85.56 | 167,013 |
| 2018-01-05 | Gryska David W (Executive Vice President, CFO) | Sale | 6,760 | 98.87 | 668,361 |
| 2018-01-05 | Gryska David W (Executive Vice President, CFO) | Option Ex | 6,760 | 83.83 | 566,690 |
| 2018-01-02 | Iyengar Vijay K (EVP GPS, BD, & Licensing) | Sale | 5,000 | 97.26 | 486,300 |
| 2018-01-02 | Iyengar Vijay K (EVP GPS, BD, & Licensing) | Option Ex | 5,000 | 72.86 | 364,300 |
| 2017-12-01 | Huber Reid M (EVP, Chief Scientific Officer) | Sale | 696 | 98.01 | 68,214 |
| 2017-11-16 | Friedman Paul A (Director) | Sale | 28,507 | 105.24 | 3,000,076 |
| 2017-11-02 | Gryska David W (Executive Vice President, CFO) | Sale | 3,915 | 105.63 | 413,541 |
| 2017-09-18 | Hoppenot Herve (Chairman / CEO) | Sale | 70,502 | 119.45 | 8,421,463 |
| 2017-09-14 | Flannelly Barry P (EVP & General Manager US) | Sale | 714 | 124.25 | 88,714 |
| 2017-09-08 | Baker Brothers Life Sciences Lp (Director) | Buy | 100,000 | 132.00 | 13,200,000 |
| 2017-09-05 | Trower Paul (Principal Accounting Officer) | Sale | 3,000 | 138.41 | 415,230 |
| 2017-09-05 | Trower Paul (Principal Accounting Officer) | Option Ex | 3,000 | 17.79 | 53,370 |
| 2017-09-01 | Siegel Eric H. (EVP, General Counsel) | Sale | 1,820 | 137.40 | 250,068 |
| 2017-09-01 | Siegel Eric H. (EVP, General Counsel) | Option Ex | 1,820 | 64.55 | 117,481 |
| 2017-08-31 | Swain Paula J (EVP, Human Resources) | Sale | 20,000 | 140.00 | 2,800,000 |
| 2017-08-31 | Swain Paula J (EVP, Human Resources) | Option Ex | 20,000 | 17.79 | 355,800 |
| 2017-08-29 | Stein Steven H (EVP & Chief Medical Officer) | Sale | 2,111 | 125.00 | 263,875 |
| 2017-08-29 | Stein Steven H (EVP & Chief Medical Officer) | Option Ex | 2,111 | 89.42 | 188,771 |
| 2017-08-04 | Trower Paul (Principal Accounting Officer) | Sale | 3,000 | 125.25 | 375,750 |
| 2017-08-04 | Trower Paul (Principal Accounting Officer) | Option Ex | 3,000 | 17.79 | 53,370 |
| 2017-08-01 | Siegel Eric H. (EVP, General Counsel) | Sale | 1,820 | 132.92 | 241,914 |
| 2017-08-01 | Siegel Eric H. (EVP, General Counsel) | Option Ex | 1,820 | 64.55 | 117,481 |
| 2017-07-20 | Stein Steven H (EVP & Chief Medical Officer) | Sale | 6,485 | 131.09 | 850,118 |
| 2017-07-20 | Stein Steven H (EVP & Chief Medical Officer) | Option Ex | 6,485 | 89.42 | 579,908 |
| 2017-07-05 | Trower Paul (Principal Accounting Officer) | Sale | 3,000 | 126.18 | 378,540 |
| 2017-07-05 | Trower Paul (Principal Accounting Officer) | Option Ex | 3,000 | 17.79 | 53,370 |
| 2017-07-03 | Siegel Eric H. (EVP, General Counsel) | Sale | 1,820 | 126.20 | 229,684 |
| 2017-07-03 | Siegel Eric H. (EVP, General Counsel) | Option Ex | 1,820 | 64.55 | 117,481 |
| 2017-06-30 | Gryska David W (Executive Vice President, CFO) | Sale | 599 | 129.74 | 77,714 |
| 2017-06-30 | Gryska David W (Executive Vice President, CFO) | Option Ex | 599 | 73.21 | 43,852 |
| 2017-06-20 | Stein Steven H (EVP & Chief Medical Officer) | Sale | 9,883 | 125.00 | 1,235,375 |
| 2017-06-20 | Stein Steven H (EVP & Chief Medical Officer) | Option Ex | 9,883 | 92.22 | 911,410 |
| 2017-06-12 | Gryska David W (Executive Vice President, CFO) | Sale | 16,756 | 116.60 | 1,953,749 |
| 2017-06-12 | Gryska David W (Executive Vice President, CFO) | Option Ex | 16,756 | 73.21 | 1,226,706 |
| 2017-06-06 | Siegel Eric H. (EVP, General Counsel) | Option Ex | 1,292 | 68.88 | 88,992 |
| 2017-06-05 | Trower Paul (Principal Accounting Officer) | Sale | 3,000 | 132.50 | 397,500 |
| 2017-06-05 | Trower Paul (Principal Accounting Officer) | Option Ex | 3,000 | 17.79 | 53,370 |
| 2017-06-01 | Siegel Eric H. (EVP, General Counsel) | Sale | 1,820 | 130.00 | 236,600 |
| 2017-06-01 | Siegel Eric H. (EVP, General Counsel) | Option Ex | 1,820 | 64.55 | 117,481 |
| 2017-05-31 | Bienaime Jean Jacques (Director) | Buy | 500 | 131.80 | 65,900 |
| 2017-05-15 | Bienaime Jean Jacques (Director) | Buy | 500 | 115.00 | 57,500 |
| 2017-05-08 | Huber Reid M (EVP, Chief Scientific Officer) | Sale | 8,577 | 119.21 | 1,022,464 |
| 2017-05-05 | Trower Paul (Principal Accounting Officer) | Sale | 3,000 | 121.70 | 365,100 |
| 2017-05-05 | Trower Paul (Principal Accounting Officer) | Option Ex | 3,000 | 17.79 | 53,370 |
| 2017-05-01 | Flannelly Barry P (EVP & General Manager US) | Sale | 5,296 | 124.68 | 660,305 |
| 2017-05-01 | Flannelly Barry P (EVP & General Manager US) | Option Ex | 2,064 | 48.44 | 99,980 |
| 2017-05-01 | Siegel Eric H. (EVP, General Counsel) | Sale | 1,820 | 124.73 | 227,008 |
| 2017-05-01 | Siegel Eric H. (EVP, General Counsel) | Option Ex | 1,820 | 64.55 | 117,481 |
| 2017-04-28 | Bienaime Jean Jacques (Director) | Buy | 500 | 124.26 | 62,130 |
| 2017-04-28 | Gryska David W (Executive Vice President, CFO) | Sale | 1,389 | 124.26 | 172,597 |
| 2017-04-28 | Gryska David W (Executive Vice President, CFO) | Option Ex | 1,389 | 67.06 | 93,146 |
| 2017-04-27 | Baker Brothers Life Sciences Lp (Director) | Option Ex | 60,000 | 7.26 | 435,600 |
| 2017-04-13 | Bienaime Jean Jacques (Director) | Buy | 1,000 | 139.66 | 139,660 |
| 2017-04-10 | Siegel Eric H. (EVP, General Counsel) | Sale | 4,043 | 140.18 | 566,747 |
| 2017-04-10 | Siegel Eric H. (EVP, General Counsel) | Option Ex | 4,043 | 41.44 | 167,521 |
| 2017-04-10 | Gryska David W (Executive Vice President, CFO) | Sale | 41,528 | 138.00 | 5,730,864 |
| 2017-04-10 | Gryska David W (Executive Vice President, CFO) | Option Ex | 41,528 | 67.06 | 2,784,867 |
| 2017-04-07 | Stein Steven H (EVP & Chief Medical Officer) | Sale | 32,000 | 137.90 | 4,412,640 |
| 2017-04-07 | Stein Steven H (EVP & Chief Medical Officer) | Option Ex | 32,000 | 92.22 | 2,951,040 |
| 2017-04-07 | Bienaime Jean Jacques (Director) | Buy | 1,000 | 139.48 | 139,480 |
| 2017-03-17 | Friedman Paul A (Director) | Sale | 41,693 | 148.18 | 6,178,068 |
| 2017-03-17 | Friedman Paul A (Director) | Option Ex | 41,693 | 18.32 | 763,815 |
| 2017-03-17 | Brooke Paul A (Director) | Sale | 20,000 | 147.75 | 2,955,000 |
| 2017-03-17 | Brooke Paul A (Director) | Option Ex | 20,000 | 7.26 | 145,200 |
| 2017-03-16 | Friedman Paul A (Director) | Sale | 8,307 | 151.45 | 1,258,095 |
| 2017-03-16 | Friedman Paul A (Director) | Option Ex | 8,307 | 18.32 | 152,184 |
| 2017-02-27 | Huber Reid M (EVP, Chief Scientific Officer) | Sale | 2,008 | 131.88 | 264,815 |
| 2017-02-23 | Friedman Paul A (Director) | Sale | 50,000 | 120.32 | 6,016,000 |
| 2017-02-23 | Friedman Paul A (Director) | Option Ex | 50,000 | 18.32 | 916,000 |
| 2017-01-09 | Huber Reid M (EVP, Chief Scientific Officer) | Sale | 11,739 | 113.55 | 1,332,963 |
| 2016-11-15 | Swain Paula J (EVP, Human Resources) | Sale | 10,000 | 103.26 | 1,032,600 |
| 2016-11-15 | Swain Paula J (EVP, Human Resources) | Option Ex | 10,000 | 14.72 | 147,200 |
| 2016-11-09 | Huber Reid M (EVP, Chief Scientific Officer) | Sale | 2,715 | 109.95 | 298,514 |
| 2016-10-20 | Swain Paula J (EVP, Human Resources) | Sale | 10,000 | 90.00 | 900,000 |
| 2016-10-20 | Swain Paula J (EVP, Human Resources) | Option Ex | 10,000 | 14.72 | 147,200 |
| 2016-10-07 | Flannelly Barry P (EVP & General Manager US) | Sale | 24,204 | 97.00 | 2,347,788 |
| 2016-10-07 | Flannelly Barry P (EVP & General Manager US) | Option Ex | 24,204 | 48.44 | 1,172,441 |
| 2016-10-07 | Huber Reid M (EVP, Chief Scientific Officer) | Sale | 11,709 | 96.40 | 1,128,747 |
| 2016-10-07 | Huber Reid M (EVP, Chief Scientific Officer) | Option Ex | 11,709 | 18.32 | 214,508 |
| 2016-09-23 | Swain Paula J (EVP, Human Resources) | Sale | 20,000 | 90.00 | 1,800,000 |
| 2016-09-23 | Swain Paula J (EVP, Human Resources) | Option Ex | 20,000 | 14.72 | 294,400 |
| 2016-08-02 | Huber Reid M (EVP, Chief Scientific Officer) | Sale | 10,000 | 87.96 | 879,599 |
| 2016-07-29 | Swain Paula J (EVP, Human Resources) | Sale | 60,000 | 90.00 | 5,400,000 |
| 2016-07-29 | Swain Paula J (EVP, Human Resources) | Option Ex | 60,000 | 14.72 | 883,200 |
| 2016-04-01 | Brooke Paul A (Director) | Option Ex | 20,000 | 3.86 | 77,200 |
| 2016-03-17 | Baker Bros. Advisors (gp) Llc (Director) | Buy | 400,000 | 61.36 | 24,543,600 |
| 2016-03-17 | Baker Bros. Advisors (gp) Llc (Director) | Option Ex | 60,000 | 3.86 | 231,600 |
| 2016-03-15 | Baker Bros. Advisors (gp) Llc (Director) | Buy | 400,000 | 66.08 | 26,431,599 |
| 2016-02-16 | Huber Reid M (EVP, Chief Scientific Officer) | Option Ex | 5,377 | 18.32 | 98,506 |
| 2016-01-15 | Siegel Eric H. (EVP, General Counsel) | Option Ex | 2,509 | 18.32 | 45,964 |
| 2016-01-15 | Swain Paula J (EVP, Human Resources) | Sale | 13,531 | 76.96 | 1,041,345 |
| 2016-01-15 | Swain Paula J (EVP, Human Resources) | Option Ex | 13,531 | 3.11 | 42,081 |
| 2016-01-06 | Levy Richard S (EVP, Chief Drug Dev Officer) | Sale | 3,937 | 101.86 | 401,022 |
| 2016-01-06 | Levy Richard S (EVP, Chief Drug Dev Officer) | Option Ex | 3,937 | 18.32 | 72,125 |
| 2015-12-10 | Siegel Eric H. (EVP, General Counsel) | Sale | 1,936 | 107.96 | 209,010 |
| 2015-12-10 | Siegel Eric H. (EVP, General Counsel) | Option Ex | 1,936 | 18.32 | 35,467 |
| 2015-12-07 | Levy Richard S (EVP, Chief Drug Dev Officer) | Sale | 3,937 | 106.18 | 418,030 |
| 2015-12-07 | Levy Richard S (EVP, Chief Drug Dev Officer) | Option Ex | 3,937 | 18.32 | 72,125 |
| 2015-11-18 | Friedman Paul A (Director) | Sale | 125,000 | 115.27 | 14,408,750 |
| 2015-11-18 | Friedman Paul A (Director) | Option Ex | 125,000 | 17.79 | 2,223,750 |
| 2015-11-17 | Friedman Paul A (Director) | Sale | 100,000 | 112.20 | 11,220,300 |
| 2015-11-17 | Friedman Paul A (Director) | Option Ex | 100,000 | 17.79 | 1,779,000 |
| 2015-11-10 | Siegel Eric H. (EVP, General Counsel) | Sale | 2,222 | 104.86 | 232,998 |
| 2015-11-10 | Siegel Eric H. (EVP, General Counsel) | Option Ex | 2,222 | 18.32 | 40,707 |
| 2015-11-06 | Levy Richard S (EVP, Chief Drug Dev Officer) | Sale | 3,936 | 116.51 | 458,583 |
| 2015-11-06 | Levy Richard S (EVP, Chief Drug Dev Officer) | Option Ex | 3,936 | 18.32 | 72,107 |
| 2015-11-03 | Wenqing Yao (EVP, Discovery Medicinal and P) | Sale | 5,786 | 124.85 | 722,382 |
| 2015-11-03 | Wenqing Yao (EVP, Discovery Medicinal and P) | Option Ex | 5,000 | 17.79 | 88,950 |
| 2015-10-13 | Siegel Eric H. (EVP, General Counsel) | Sale | 2,222 | 101.49 | 225,510 |
| 2015-10-13 | Siegel Eric H. (EVP, General Counsel) | Option Ex | 2,222 | 18.32 | 40,707 |
| 2015-10-06 | Levy Richard S (EVP, Chief Drug Dev Officer) | Sale | 3,937 | 122.29 | 481,455 |
| 2015-10-06 | Levy Richard S (EVP, Chief Drug Dev Officer) | Option Ex | 3,937 | 18.32 | 72,125 |
| 2015-09-21 | Huber Reid M (EVP, Chief Scientific Officer) | Sale | 10,000 | 124.29 | 1,242,900 |
| 2015-09-21 | Huber Reid M (EVP, Chief Scientific Officer) | Option Ex | 10,000 | 18.32 | 183,200 |
| 2015-09-16 | Baker Bros. Advisors (gp) Llc (Director) | Option Ex | 4,623,926 | .00 | 0 |
| 2015-09-16 | Siegel Eric H. (EVP, General Counsel) | Sale | 2,222 | 130.69 | 290,393 |
| 2015-09-16 | Siegel Eric H. (EVP, General Counsel) | Option Ex | 2,222 | 18.32 | 40,707 |
| 2015-09-11 | Levy Richard S (EVP, Chief Drug Dev Officer) | Sale | 4,301 | 130.00 | 559,130 |
| 2015-09-08 | Levy Richard S (EVP, Chief Drug Dev Officer) | Sale | 3,937 | 118.90 | 468,109 |
| 2015-09-08 | Levy Richard S (EVP, Chief Drug Dev Officer) | Option Ex | 3,937 | 18.32 | 72,125 |
| 2015-08-13 | Siegel Eric H. (EVP, General Counsel) | Sale | 2,222 | 107.69 | 239,287 |
| 2015-08-13 | Siegel Eric H. (EVP, General Counsel) | Option Ex | 2,222 | 18.32 | 40,707 |
| 2015-08-07 | Huber Reid M (EVP, Chief Scientific Officer) | Option Ex | 8,397 | 18.05 | 151,607 |
| 2015-08-06 | Levy Richard S (EVP, Chief Drug Dev Officer) | Sale | 3,936 | 111.95 | 440,635 |
| 2015-08-06 | Levy Richard S (EVP, Chief Drug Dev Officer) | Option Ex | 3,936 | 18.32 | 72,107 |
| 2015-07-15 | Wenqing Yao (EVP, Discovery Medicinal and P) | Sale | 5,000 | 119.75 | 598,750 |
| 2015-07-15 | Wenqing Yao (EVP, Discovery Medicinal and P) | Option Ex | 5,000 | 17.79 | 88,950 |
| 2015-07-15 | Levy Richard S (EVP, Chief Drug Dev Officer) | Sale | 70,217 | 120.00 | 8,426,040 |
| 2015-07-15 | Levy Richard S (EVP, Chief Drug Dev Officer) | Option Ex | 70,217 | 17.79 | 1,249,160 |
| 2015-07-14 | Wenqing Yao (EVP, Discovery Medicinal and P) | Sale | 7,850 | 114.75 | 900,787 |
| 2015-07-14 | Wenqing Yao (EVP, Discovery Medicinal and P) | Option Ex | 7,850 | 14.72 | 115,552 |
| 2015-07-14 | Siegel Eric H. (EVP, General Counsel) | Sale | 2,222 | 113.61 | 252,441 |
| 2015-07-14 | Siegel Eric H. (EVP, General Counsel) | Option Ex | 2,222 | 18.32 | 40,707 |
| 2015-07-06 | Levy Richard S (EVP, Chief Drug Dev Officer) | Sale | 3,937 | 107.00 | 421,259 |
| 2015-07-06 | Levy Richard S (EVP, Chief Drug Dev Officer) | Option Ex | 3,937 | 18.32 | 72,125 |
| 2015-06-23 | Daly James M (EVP, Chief Commercial Officer) | Sale | 11,691 | 108.06 | 1,263,329 |
| 2015-06-23 | Daly James M (EVP, Chief Commercial Officer) | Option Ex | 11,691 | 29.03 | 339,366 |
| 2015-06-19 | Levy Richard S (EVP, Chief Drug Dev Officer) | Sale | 20,000 | 108.13 | 2,162,600 |
| 2015-06-19 | Levy Richard S (EVP, Chief Drug Dev Officer) | Option Ex | 20,000 | 17.79 | 355,800 |
| 2015-06-12 | Siegel Eric H. (EVP, General Counsel) | Sale | 2,223 | 105.31 | 234,104 |
| 2015-06-12 | Siegel Eric H. (EVP, General Counsel) | Option Ex | 2,223 | 18.32 | 40,725 |
| 2015-06-08 | Levy Richard S (EVP, Chief Drug Dev Officer) | Sale | 3,937 | 107.58 | 423,542 |
| 2015-06-08 | Levy Richard S (EVP, Chief Drug Dev Officer) | Option Ex | 3,937 | 18.32 | 72,125 |
| 2015-05-27 | Friedman Paul A (Director) | Sale | 69,132 | 107.42 | 7,426,505 |
| 2015-05-27 | Friedman Paul A (Director) | Option Ex | 69,132 | 14.72 | 1,017,623 |
| 2015-05-26 | Daly James M (EVP, Chief Commercial Officer) | Sale | 12,093 | 106.22 | 1,284,457 |
| 2015-05-26 | Daly James M (EVP, Chief Commercial Officer) | Option Ex | 12,093 | 29.03 | 351,035 |
| 2015-05-26 | Friedman Paul A (Director) | Sale | 127,619 | 107.27 | 13,689,434 |
| 2015-05-26 | Friedman Paul A (Director) | Option Ex | 127,619 | 14.72 | 1,878,551 |
| 2015-05-22 | Friedman Paul A (Director) | Sale | 79,592 | 108.12 | 8,605,327 |
| 2015-05-22 | Friedman Paul A (Director) | Option Ex | 79,592 | 14.72 | 1,171,594 |
| 2015-05-21 | Friedman Paul A (Director) | Sale | 22,651 | 108.83 | 2,465,221 |
| 2015-05-21 | Friedman Paul A (Director) | Option Ex | 22,651 | 14.72 | 333,422 |
| 2015-05-18 | Brooke Paul A (Director) | Option Ex | 20,000 | 7.68 | 153,600 |
| 2015-05-14 | Siegel Eric H. (EVP, General Counsel) | Sale | 2,222 | 104.99 | 233,287 |
| 2015-05-14 | Siegel Eric H. (EVP, General Counsel) | Option Ex | 2,222 | 18.32 | 40,707 |
| 2015-05-11 | Baker Bros. Advisors (gp) Llc (Director) | Option Ex | 60,000 | 7.68 | 460,800 |
| 2015-05-06 | Levy Richard S (EVP, Chief Drug Dev Officer) | Sale | 7,412 | 99.43 | 736,975 |
| 2015-05-06 | Levy Richard S (EVP, Chief Drug Dev Officer) | Option Ex | 7,412 | 18.32 | 135,787 |
| 2015-04-23 | Daly James M (EVP, Chief Commercial Officer) | Sale | 36,941 | 107.67 | 3,977,437 |
| 2015-04-23 | Daly James M (EVP, Chief Commercial Officer) | Option Ex | 36,941 | 29.03 | 1,072,323 |
| 2015-04-17 | Wenqing Yao (EVP, Discovery Medicinal and P) | Sale | 7,150 | 102.04 | 729,586 |
| 2015-04-16 | Huber Reid M (EVP, Chief Scientific Officer) | Option Ex | 10,060 | 15.28 | 153,746 |
| 2015-04-14 | Siegel Eric H. (EVP, General Counsel) | Sale | 2,222 | 98.72 | 219,355 |
| 2015-04-14 | Siegel Eric H. (EVP, General Counsel) | Option Ex | 2,222 | 18.32 | 40,707 |
| 2015-04-13 | Wenqing Yao (EVP, Discovery Medicinal and P) | Sale | 14,000 | 96.75 | 1,354,500 |
| 2015-04-13 | Wenqing Yao (EVP, Discovery Medicinal and P) | Option Ex | 14,000 | 17.79 | 249,060 |
| 2015-04-13 | Swain Paula J (EVP, Human Resources) | Sale | 16,469 | 96.29 | 1,585,800 |
| 2015-04-13 | Swain Paula J (EVP, Human Resources) | Option Ex | 16,469 | 3.11 | 51,218 |
| 2015-04-10 | Wenqing Yao (EVP, Discovery Medicinal and P) | Sale | 9,000 | 92.75 | 834,750 |
| 2015-04-10 | Wenqing Yao (EVP, Discovery Medicinal and P) | Option Ex | 9,000 | 17.79 | 160,110 |
| 2015-04-07 | Wenqing Yao (EVP, Discovery Medicinal and P) | Sale | 20,031 | 90.16 | 1,805,914 |
| 2015-04-07 | Wenqing Yao (EVP, Discovery Medicinal and P) | Option Ex | 5,000 | 17.79 | 88,950 |
| 2015-04-06 | Levy Richard S (EVP, Chief Drug Dev Officer) | Sale | 25,000 | 88.77 | 2,219,250 |
| 2015-04-06 | Levy Richard S (EVP, Chief Drug Dev Officer) | Option Ex | 25,000 | 18.32 | 458,000 |
| 2015-03-30 | Huber Reid M (EVP, Chief Scientific Officer) | Sale | 34,263 | 93.67 | 3,209,483 |
| 2015-03-30 | Huber Reid M (EVP, Chief Scientific Officer) | Option Ex | 34,263 | 18.05 | 618,618 |
| 2015-03-30 | Chardonnet Laurent (Other) | Sale | 113,776 | 93.64 | 10,653,984 |
| 2015-03-30 | Chardonnet Laurent (Other) | Option Ex | 113,776 | 16.04 | 1,825,308 |
| 2015-03-16 | Swain Paula J (EVP, Human Resources) | Sale | 17,500 | 89.97 | 1,574,475 |
| 2015-03-16 | Swain Paula J (EVP, Human Resources) | Option Ex | 17,500 | 3.11 | 54,425 |
| 2015-03-12 | Siegel Eric H. (EVP, General Counsel) | Sale | 2,222 | 89.72 | 199,346 |
| 2015-03-12 | Siegel Eric H. (EVP, General Counsel) | Option Ex | 2,222 | 18.32 | 40,707 |
| 2015-03-12 | Ariko Barry A (Director) | Sale | 80,000 | 89.27 | 7,141,600 |
| 2015-03-12 | Ariko Barry A (Director) | Option Ex | 80,000 | 5.96 | 476,800 |
| 2015-03-10 | Wenqing Yao (EVP, Discovery Medicinal and P) | Option Ex | 4,404 | 18.05 | 79,514 |
| 2015-03-06 | Levy Richard S (EVP, Chief Drug Dev Officer) | Sale | 25,000 | 89.91 | 2,247,750 |
| 2015-03-06 | Levy Richard S (EVP, Chief Drug Dev Officer) | Option Ex | 25,000 | 18.32 | 458,000 |
| 2015-03-05 | Siegel Eric H. (EVP, General Counsel) | Sale | 13,333 | 90.00 | 1,199,970 |
| 2015-03-05 | Siegel Eric H. (EVP, General Counsel) | Option Ex | 13,333 | 18.32 | 244,260 |
| 2015-03-05 | De Schutter Richard U (Director) | Sale | 40,000 | 91.94 | 3,677,400 |
| 2015-03-05 | De Schutter Richard U (Director) | Option Ex | 40,000 | 17.09 | 683,720 |
| 2015-02-25 | Siegel Eric H. (EVP, General Counsel) | Sale | 13,333 | 85.00 | 1,133,305 |
| 2015-02-25 | Siegel Eric H. (EVP, General Counsel) | Option Ex | 13,333 | 18.32 | 244,260 |
| 2015-02-24 | Daly James M (EVP, Chief Commercial Officer) | Sale | 8,334 | 81.77 | 681,471 |
| 2015-02-24 | Daly James M (EVP, Chief Commercial Officer) | Option Ex | 8,334 | 16.62 | 138,511 |
| 2015-02-23 | Daly James M (EVP, Chief Commercial Officer) | Sale | 2,778 | 83.44 | 231,796 |
| 2015-02-23 | Daly James M (EVP, Chief Commercial Officer) | Option Ex | 2,778 | 18.32 | 50,892 |
| 2015-02-18 | Ariko Barry A (Director) | Sale | 20,000 | 78.43 | 1,568,600 |
| 2015-02-18 | Ariko Barry A (Director) | Option Ex | 20,000 | 7.68 | 153,600 |
| 2015-02-17 | Levy Richard S (EVP, Chief Drug Dev&Medical Of) | Sale | 12,000 | 76.90 | 922,800 |
| 2015-02-17 | Levy Richard S (EVP, Chief Drug Dev&Medical Of) | Option Ex | 12,000 | 16.25 | 195,060 |
| 2015-02-17 | Swain Paula J (EVP, Human Resources) | Sale | 17,500 | 76.90 | 1,345,750 |
| 2015-02-17 | Swain Paula J (EVP, Human Resources) | Option Ex | 17,500 | 3.11 | 54,425 |
| 2015-02-13 | Friedman Paul A (Director) | Sale | 120,000 | 74.32 | 8,918,400 |
| 2015-02-06 | Levy Richard S (EVP, Chief Drug Dev&Medical Of) | Sale | 25,000 | 75.11 | 1,877,750 |
| 2015-02-06 | Levy Richard S (EVP, Chief Drug Dev&Medical Of) | Option Ex | 25,000 | 18.32 | 458,000 |
| 2015-01-26 | Siegel Eric H. (EVP, General Counsel) | Sale | 1,042 | 80.00 | 83,360 |
| 2015-01-26 | Siegel Eric H. (EVP, General Counsel) | Option Ex | 1,042 | 17.79 | 18,537 |
| 2015-01-23 | Daly James M (EVP, Chief Commercial Officer) | Sale | 11,109 | 77.68 | 862,947 |
| 2015-01-23 | Daly James M (EVP, Chief Commercial Officer) | Option Ex | 11,109 | 17.19 | 190,930 |
| 2015-01-23 | Siegel Eric H. (EVP, General Counsel) | Sale | 11,458 | 80.00 | 916,640 |
| 2015-01-23 | Siegel Eric H. (EVP, General Counsel) | Option Ex | 11,458 | 17.79 | 203,837 |
| 2015-01-22 | Siegel Eric H. (EVP, General Counsel) | Sale | 1,042 | 77.99 | 81,265 |
| 2015-01-22 | Siegel Eric H. (EVP, General Counsel) | Option Ex | 1,042 | 17.79 | 18,537 |
| 2015-01-20 | Swain Paula J (EVP, Human Resources) | Sale | 17,500 | 74.17 | 1,297,975 |
| 2015-01-20 | Swain Paula J (EVP, Human Resources) | Option Ex | 17,500 | 3.11 | 54,425 |
| 2015-01-16 | Levy Richard S (EVP, Chief Drug Dev&Medical Of) | Sale | 12,000 | 73.07 | 876,839 |
| 2015-01-16 | Levy Richard S (EVP, Chief Drug Dev&Medical Of) | Option Ex | 12,000 | 14.72 | 176,640 |
| 2015-01-08 | Siegel Eric H. (EVP, General Counsel) | Sale | 15,626 | 75.00 | 1,171,950 |
| 2015-01-08 | Siegel Eric H. (EVP, General Counsel) | Option Ex | 15,626 | 16.53 | 258,250 |
| 2015-01-06 | Levy Richard S (EVP, Chief Drug Dev&Medical Of) | Sale | 25,000 | 71.84 | 1,796,000 |
| 2015-01-06 | Levy Richard S (EVP, Chief Drug Dev&Medical Of) | Option Ex | 25,000 | 18.32 | 458,000 |
| 2015-01-05 | Swain Paula J (EVP, Human Resources) | Sale | 17,500 | 73.90 | 1,293,250 |
| 2015-01-05 | Swain Paula J (EVP, Human Resources) | Option Ex | 17,500 | 3.11 | 54,425 |
Insider trading activities including stock purchases, stock sales, and option exercises of INCY listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Incyte Corp (symbol INCY, CIK number 879169) see the Securities and Exchange Commission (SEC) website.